Leukemia Research
Volume 30, Issue 2 , Pages 136-144 , February 2006

Cytotoxic effect of a lipophilic alkylating agent after incorporation into low density lipoprotein or emulsions: Studies in human leukemic cells

  • Michèle Masquelier

      Affiliations

    • Department of Medicine, Division of Clinical Pharmacology, Karolinska Institute/Karolinska University Hospital, S-171 76 Stockholm, Sweden
    • Corresponding Author InformationCorresponding author. Tel.: +46 851774461; fax: +46 8331343.
    • ,
  • Bo Lundberg

      Affiliations

    • Department of Biochemistry and Pharmacy, Åbo Akademi University, BioCity, P.O. Box 66, 20520 Åbo, Finland
    • ,
  • Curt Peterson

      Affiliations

    • Division of Clinical Pharmacology, Department of Medicine and Care, Faculty of Health Sciences, Linköping University, SE-581 85 Linköping, Sweden
    • ,
  • Sigurd Vitols

      Affiliations

    • Department of Medicine, Division of Clinical Pharmacology, Karolinska Institute/Karolinska University Hospital, S-171 76 Stockholm, Sweden

Received 11 April 2005 ,Revised 17 June 2005 ,Accepted 18 June 2005.

References 

  1. de Duve C, de Barsy T, Poole B, Trouet A, Tulkens P, Van Hoof F. Commentary. Lysosomotropic agents. Biochem Pharmacol. 1974;23:2495–2531
  2. de Duve C, Trouet A, Campeneere DD, Baurian R. Liposomes as lysosomotropic carriers. Ann N Y Acad Sci. 1978;308:226–234
  3. Ho YK, Smith RG, Brown MS, Goldstein JL. Low-density lipoprotein (LDL) receptor activity in human acute myelogenous leukemia cells. Blood. 1978;52:1099–1114
  4. Gal D, MacDonald PC, Porter JC, Simpson ER. Cholesterol metabolism in cancer cells in monolayer culture. VI. Metabolism of high-density lipoprotein. Arch Biochem Biophys. 1982;214:726–733
  5. Vitols S, Gahrton G, Ost A, Peterson C. Elevated low density lipoprotein receptor activity in leukemic cells with monocytic differentiation. Blood. 1984;63:1186–1193
  6. Vitols S, Soderberg-Reid K, Masquelier M, Sjostrom B, Peterson C. Low density lipoprotein for delivery of a water-insoluble alkylating agent to malignant cells. In vitro and in vivo studies of a drug-lipoprotein complex. Br J Cancer. 1990;62:724–729
  7. Samuels BL, Bitran JD. High-dose intravenous melphalan: a review. J Clin Oncol. 1995;13:1786–1799
  8. Goldstein JL, Brown MS. The low-density lipoprotein pathway and its relation to atherosclerosis. Annu Rev Biochem. 1977;46:897–930
  9. Sakashita AM, Bydlowski SP, Chamone DA, Maranhao RC. Plasma kinetics of an artificial emulsion resembling chylomicrons in patients with chronic lymphocytic leukemia. Ann Hematol. 2000;79:687–690
  10. Lundberg B. Preparation of drug-carrier emulsions stabilized with phosphatidylcholine-surfactant mixtures. J Pharm Sci. 1994;83:72–75
  11. Tatidis L, Masquelier M, Vitols S. Elevated uptake of low density lipoprotein by drug resistant human leukemic cell lines. Biochem Pharmacol. 2002;63:2169–2180
  12. Masquelier M, Zhou QF, Gruber A, Vitols S. Relationship between daunorubicin concentration and apoptosis induction in leukemic cells. Biochem Pharmacol. 2004;67:1047–1056
  13. Havel RJ, Eder HA, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest. 1955;34:1345–1353
  14. Masquelier M, Vitols S, Peterson C. Low-density lipoprotein as a carrier of antitumoral drugs: in vivo fate of drug-human low-density lipoprotein complexes in mice. Cancer Res. 1986;46:3842–3847
  15. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65:55–63
  16. Paul C, Lonnqvist B, Gahrton G, Lockner D, Peterson C. Reducing the cardiotoxicity of anthracyclines by complex-binding to DNA: report of three cases. Cancer. 1981;48:1531–1534
  17. Paul C, Bjorkholm M, Christenson I, Engstedt L, Gahrton G, Hast R, et al. Comparison of daunorubicin and daunorubicin–DNA complex in the treatment of acute nonlymphoblastic leukemia. Cancer Chemother Pharmacol. 1981;6:65–73
  18. Schroder C, Eckert K, Maurer HR. Tributyrin induces growth inhibitory and differentiating effects on HT-29 colon cancer cells in vitro. Int J Oncol. 1998;13:1335–1340
  19. Dintaman JM, Silverman JA. Inhibition of p-glycoprotein by d-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS). Pharm Res. 1999;16:1550–1556
  20. Zhou R, Wang Y, Gruber A, Larsson R, Castanos-Velez E, Liliemark E, et al. Topoisomerase II-mediated alterations of K562 drug resistant sublines. Med Oncol. 1999;16:191–198
  21. Bosanquet AG. Stability of melphalan solutions during preparation and storage. J Pharm Sci. 1985;74:348–351
  22. Vogelzang NJ. Continuous infusion chemotherapy: a critical review. J Clin Oncol. 1984;2:1289–1304
  23. Pinguet F, Culine S, Bressolle F, Astre C, Serre MP, Chevillard C, et al. A phase I and pharmacokinetic study of melphalan using a 24-h continuous infusion in patients with advanced malignancies. Clin Cancer Res. 2000;6:57–63
  24. Bosanquet AG, Bird MC. Degradation of melphalan in vitro: rationale for the use of continuous exposure in chemosensitivity assays. Cancer Chemother Pharmacol. 1988;21:211–215

PII: S0145-2126(05)00228-6

doi: 10.1016/j.leukres.2005.06.012

Leukemia Research
Volume 30, Issue 2 , Pages 136-144 , February 2006

Article Tools

* Image Usage & Resolution